Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1983; 2:174-179
© 1983 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Douglas, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douglas, J., Jr

Hemodynamic effects of nifedipine in primary pulmonary hypertension

JS Douglas Jr

Progressive dyspnea and syncope occurred in a young woman with primary pulmonary hypertension despite therapy with hydralazine. Abnormal pulmonary artery reactivity was documented by an additional increase in pulmonary artery pressure and pulmonary vascular resistance during exercise and after an episode of hydralazine-induced hypotension. Nifedipine reduced rest and exercise pulmonary artery pressure, pulmonary vascular resistance and right ventricular stroke work, and increased cardiac output and markedly improved exercise capacity. Reevaluation after 6 months showed persistence of the favorable hemodynamic and clinical effects. Vasodilator therapy, potentially hazardous because of effects on systemic vascular resistance, can be evaluated safely only with hemodynamic monitoring. Nifedipine may be a useful drug in selected patients with primary pulmonary hypertension.


This article has been cited by other articles:


Home page
ANGIOLOGYHome page
M. A. Alpert, M. D. Concannon, B. Mukerji, and V. Mukerji
Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations: Part I: Primary Pulmonary Hypertension
Angiology, August 1, 1994; 45(8): 667 - 676.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
M. PACKER
Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards
Ann Intern Med, August 1, 1985; 103(2): 258 - 270.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
M. L. Schwartz, H. H. Rotmensch, P. H. Vlasses, and R. K. Ferguson
Calcium Blockers in Smooth-Muscle Disorders: Current Status
Arch Intern Med, July 1, 1984; 144(7): 1425 - 1429.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement